search

Active clinical trials for "Anemia, Sickle Cell"

Results 901-910 of 922

GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis

Patients With Thalassemia Intermedia,Congenital Dyserythropoietic Anemia Type I

Patients with thalassemia intermedia, congenital dyserythropoietic anemia type I , and sideroblastic anemia were found to express very high levels of serum GDF15, and this contributed to the inappropriate suppression of hepcidin with subsequent secondary iron overload.The aim of our present study is to asses the levels of GDF15 and hepcidin in patients with Sickle cell disease and hereditary spherocytosis

Unknown status2 enrollment criteria

Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia

Sickle Cell Anemia

The purpose of this study is to use comprehensive exercise testing to examine longitudinal changes in exercise capacity over a 2 year period in children and young adults with sickle cell anemia.

Unknown status5 enrollment criteria

Risk Factors for Allo-immunization in Sickle Cell Disease

Sickle Cell Disease

Sickle cell patients have a high prevalence of alloimmunization. This high rate of alloimmunization can be partially explained by the existence of an antigenic difference between the predominantly Caucasian donor population and the sickle cell patients of African origin. Genetic and environmental risk factors have also been described. The main risk factors that have been shown in retrospective or cross-sectional studies are some HLA alleles, the age of the patient, the number of leukocyte-depleted erythrocyte concentrates (CED) transfused, the number of transfusion episodes, the age of the CEDs, the existence of an inflammatory event at the time of transfusion and the presence of anti-erythrocyte autoantibodies.There is also evidence of an impaired TH response but the underlying immunological mechanism is not fully understood. The aim of this study is to study the prevalence and the risk factors for anti-erythrocyte alloimmunization in pediatric and adult patients with Sickle Cell Disease (with a SS genotype) who are being followed at Queen Fabiola University Children's Hospital (HUDERF) and at the CHU Brugmann Hospital. The identification of risk factors would allow the investigators to improve, or at least adapt, their transfusion policy to certain clinical or immuno-haematological situations.

Withdrawn2 enrollment criteria

Medication Adherence and Non-adherence in Adults With Rare Disease

Cystic FibrosisHemophilia A4 more

The purpose of this study is to use the Medication Adherence Reasons Scale (MAR-Scale) to determine the extent of non-adherence to specific medications indicated to treat cystic fibrosis, hemophilia (A or B), idiopathic pulmonary fibrosis, myasthenia gravis, and sickle cell disease, and to identify the top patient-reported reasons for non-adherence. Internal reliability of the MAR-Scale will also be assessed in each condition.

Withdrawn12 enrollment criteria

Near Infrared Spectroscopy in Sickle Cell Pediatric Patients

Sickle Cell Disease

Endothelial dysfunction contributes to vaso-occlusion and acute pain in sickle cell disease. Near infrared spectroscopy (NIRS) technology can measure tissue oxygenation and endothelial function. The main objective of this study is to study the natural history of tissue muscle oxygenation using NIRS in pediatric sickle cell subjects experiencing acute pain and pediatric sickle cell patients in steady-state.

Withdrawn38 enrollment criteria

Study of Blood Platelets in Sickle Cell Disease

Sickle Cell Disease

We are studying if sickle cell disease blood platelets are larger than normal and how they may cause obstruction of blood vessels. We are also trying to study the reasons why large platelets are found in patients with sickle cell disease.

Withdrawn5 enrollment criteria

MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients

Sickle Cell Disease

The purpose of this Cohort Treatment Plan is to allow access to crizanlizumab (SEG101) for eligible patients diagnosed with sickle cell disease (SCD) to prevent or reduce the frequency of vaso-occlusive crises (VOC). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Available37 enrollment criteria

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment...

Sickle Cell Disease

The intent of this open-label, multicenter expanded access program (EAP) is to provide early access to voxelotor prior to market authorization

No longer available17 enrollment criteria

Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics

AlloimmunizationSickle Cell Disease

The focus of the study is the pathophysiological mechanism of allo-antibody formation after red blood cell transfusion in sickle cell disease patients.

Unknown status4 enrollment criteria

Neutrophil Extracellular Traps and Sickle Cell Disease

Sickle Cell Anemia

NETs formation in vaso-occlusive events in sickle cell disease and the role of hydroxyurea treatment.The study hypothesis is that NETs formation by neutrophils has a role in the induction of vaso occlusive disease in blood vessels. It is possible that high leukocyte count in children with sickle cell anemia is a bad prognostic sign due to NETs formation supporting occlusion of peripheral and central blood vessels.Hydroxyurea treatment might prevent vaso occlusive syndrome not only by increasing HbF but also by decreasing neutrophil count and inhibiting NETs formation.

Unknown status2 enrollment criteria
1...90919293

Need Help? Contact our team!


We'll reach out to this number within 24 hrs